Comparative assessment of the absorption of a generic formulation of N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet against the innovator N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet conducted under fasting conditions and at steady state in healthy male and female volunteers.

Multiple dose, crossover study design whereby each participant receives the test formulation of 2 mg N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet on five occasions and the innovator formulation of 2 mg N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet on five occasions with each dosing period. There will be a minimum of 10 days between each dosing period. The intervention for this trial is the test tablet formulation. On study days 1-5 participants will receive 5 daily doses of one formulation (either the test or innovator) and on study days 15-19 they will receive 5 daily doses of the other formulation (either the innovator or test). No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for water consumed with the dose). Participants are required not to eat for 4 hours before receiving each dose on study days 1 to 4 and 15 to 18. On study days 5 and 19 subjects will report to the Zenith Clinical Site for dosing and observation of adverse events and the provision of one blood sample. They are required to stay at the clinical site for 24 hours after dosing. On study days 1 to 4 and 15 to 18 subjects will report to Zenith Technology for dosing and the provision of one blood sample. On study day 5 and 19 no water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with the dose) and subjects are required to fast for 8 hours prior to receiving the dose and approximately 4 hours after receiving each dose. Bathroom visits will be supervised to ensure no unauthorised water or food intake and for personal safety. Participants will be confined at the Clinical Site for 8 hours prior to dosing to ensure compliance can be monitored and for 24 hours after dosing. Standard meals will be consumed at the Clinical Site on study days 5 and 19 with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site prior to dosing. Pre and post study laboratory tests will be completed to assess the health of participants along with HIV, Hepatitis and drugs of abuse testing.